ISS Stage II Plasma Cell Myeloma: Clinical Trials

3 trials for ISS Stage II Plasma Cell Myeloma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 unknown. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Unknown 1
Phase 22Completed 1, Recruiting 1

Follow ISS Stage II Plasma Cell Myeloma: new trials by email Literature Review of ISS Stage II Plasma Cell Myeloma trials Research Report on ISS Stage II Plasma Cell Myeloma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Pembrolizumab, Radiation Therapy - ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma
Phase 1 / Phase 2CompletedEmory University252018-05-292024-09-04
Personalized NK Cell Therapy in CBT
Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center1002016-05-192026-07-30
NK Cells in Cord Blood Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Phase 1UnknownM.D. Anderson Cancer Center132013-05-032020-02-11

Narrower conditions

Hodgkin Disease (2)  ·  Leukemia, Biphenotypic, Acute (2)  ·  Leukemia, Myeloid, Accelerated Phase (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Leukemia, Myeloid, Chronic-Phase (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Myelodysplastic Syndromes (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic-Myeloproliferative Diseases (1)

Broader conditions

Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Bone Marrow Diseases (2)  ·  Chronic Disease (2)  ·  Disease Attributes (2)  ·  Leukemia (2)  ·  Leukemia, Lymphoid (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Leukemia, Myeloid (2)  ·  Lymphatic Diseases (2)

Interventions

CT-P10 (2)  ·  Cord Blood Stem Cell Transplantation (2)  ·  Cyclophosphamide (2)  ·  Melphalan (2)  ·  Rituximab (2)  ·  Whole-Body Irradiation (2)  ·  fludarabine phosphate (2)  ·  Antilymphocyte Serum (1)  ·  Busulfan (1)  ·  Clofarabine (1)  ·  Lenalidomide (1)  ·  Mycophenolic Acid (1)  ·  Radiotherapy (1)  ·  Tacrolimus (1)  ·  pembrolizumab (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Emory University (1)

Countries

United States (3)

Top investigators

Chitra Hosing (1)  ·  Mohammad K. Khan, MD, PhD (1)  ·  Warren Fingrut, MD (1)

Results publications

PMID 38797190

NIH funding

P30CA016672 (1), P30CA138292 (1), R01CA211044 (1)